Ptc Therapeutics Stock Annual Yield

PTCT Stock

USD 45.11 0.90 1.96%

PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PTC Therapeutics Company Annual Yield Analysis

PTC Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

PTC Annual Yield Driver Correlations

Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Annual Yield. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.24	0.66	0.65	0.67	0.92	0.78	0.27	0.48	-0.87	0.86	0.94	0.51	0.89	-0.85	0.94	0.81	0.24	0.69	0.84	0.93
Total Stockholder Equity	-0.24		0.0	-0.79	0.23	-0.6	-0.57	-0.01	-0.84	0.65	-0.63	-0.35	-0.64	-0.08	0.61	-0.29	-0.7	-0.46	-0.26	-0.08	-0.52
Accounts Payable	0.66	0.0		0.14	0.49	0.54	0.6	0.4	-0.01	-0.56	0.59	0.52	0.21	0.74	-0.6	0.69	0.45	0.2	0.03	0.43	0.62
Long Term Debt	0.65	-0.79	0.14		0.14	0.85	0.65	-0.09	0.95	-0.88	0.84	0.78	0.81	0.49	-0.76	0.61	0.91	0.41	0.7	0.5	0.76
Short Term Investments	0.67	0.23	0.49	0.14		0.46	0.42	0.37	0.03	-0.35	0.27	0.68	0.24	0.57	-0.25	0.58	0.26	0.38	0.46	0.86	0.57
Total Liab	0.92	-0.6	0.54	0.85	0.46		0.87	0.22	0.74	-0.98	0.96	0.91	0.68	0.76	-0.95	0.88	0.95	0.37	0.67	0.72	0.97
Property Plant Equipment	0.78	-0.57	0.6	0.65	0.42	0.87		0.63	0.5	-0.86	0.85	0.71	0.73	0.67	-0.87	0.77	0.76	0.45	0.4	0.51	0.88
Current Deferred Revenue	0.27	-0.01	0.4	-0.09	0.37	0.22	0.63		-0.24	-0.16	0.17	0.1	0.3	0.23	-0.26	0.25	-0.01	0.27	-0.07	0.11	0.28
Net Debt	0.48	-0.84	-0.01	0.95	0.03	0.74	0.5	-0.24		-0.76	0.72	0.65	0.68	0.29	-0.65	0.45	0.83	0.45	0.6	0.42	0.64
Retained Earnings	-0.87	0.65	-0.56	-0.88	-0.35	-0.98	-0.86	-0.16	-0.76		-0.99	-0.88	-0.73	-0.78	0.95	-0.88	-0.97	-0.4	-0.63	-0.63	-0.94
Net Receivables	0.86	-0.63	0.59	0.84	0.27	0.96	0.85	0.17	0.72	-0.99		0.83	0.67	0.78	-0.98	0.86	0.95	0.3	0.56	0.56	0.91
Total Current Assets	0.94	-0.35	0.52	0.78	0.68	0.91	0.71	0.1	0.65	-0.88	0.83		0.65	0.82	-0.77	0.87	0.85	0.39	0.77	0.88	0.92
Short Term Debt	0.51	-0.64	0.21	0.81	0.24	0.68	0.73	0.3	0.68	-0.73	0.67	0.65		0.46	-0.57	0.5	0.66	0.56	0.5	0.34	0.61
Common Stock	0.89	-0.08	0.74	0.49	0.57	0.76	0.67	0.23	0.29	-0.78	0.78	0.82	0.46		-0.75	0.94	0.67	0.23	0.59	0.67	0.78
Net Tangible Assets	-0.85	0.61	-0.6	-0.76	-0.25	-0.95	-0.87	-0.26	-0.65	0.95	-0.98	-0.77	-0.57	-0.75		-0.86	-0.91	-0.24	-0.51	-0.52	-0.9
Capital Surpluse	0.94	-0.29	0.69	0.61	0.58	0.88	0.77	0.25	0.45	-0.88	0.86	0.87	0.5	0.94	-0.86		0.8	0.33	0.69	0.77	0.91
Long Term Debt Total	0.81	-0.7	0.45	0.91	0.26	0.95	0.76	-0.01	0.83	-0.97	0.95	0.85	0.66	0.67	-0.91	0.8		0.32	0.63	0.6	0.91
Short Long Term Debt	0.24	-0.46	0.2	0.41	0.38	0.37	0.45	0.27	0.45	-0.4	0.3	0.39	0.56	0.23	-0.24	0.33	0.32		0.31	0.41	0.43
Net Invested Capital	0.69	-0.26	0.03	0.7	0.46	0.67	0.4	-0.07	0.6	-0.63	0.56	0.77	0.5	0.59	-0.51	0.69	0.63	0.31		0.77	0.64
Net Working Capital	0.84	-0.08	0.43	0.5	0.86	0.72	0.51	0.11	0.42	-0.63	0.56	0.88	0.34	0.67	-0.52	0.77	0.6	0.41	0.77		0.79
Capital Stock	0.93	-0.52	0.62	0.76	0.57	0.97	0.88	0.28	0.64	-0.94	0.91	0.92	0.61	0.78	-0.9	0.91	0.91	0.43	0.64	0.79

Click cells to compare fundamentals

Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.

Competition

Predict PTC Therapeutics

In accordance with the recently published financial statements, PTC Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

PTC Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	2.8B	4.0B	2.8B	2.7B	2.1B	1.3B
Enterprise Value	2.5B	4.2B	2.5B	3.0B	3.7B	3.9B

PTC Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

PTC Fundamentals

	Return On Equity	-77.4
	Return On Asset	-0.0515
	Profit Margin	(0.50) %
	Operating Margin	(0.26) %
	Current Valuation	2.87 B
	Shares Outstanding	77.13 M
	Shares Owned By Insiders	2.34 %
	Shares Owned By Institutions	97.66 %
	Number Of Shares Shorted	4.67 M
	Price To Earning	(5.67) X
	Price To Book	1,743 X
	Price To Sales	3.86 X
	Revenue	937.82 M
	Gross Profit	2.63 M
	EBITDA	(330.34 M)
	Net Income	(626.6 M)
	Cash And Equivalents	288.43 M
	Cash Per Share	4.01 X
	Total Debt	2.23 B
	Current Ratio	1.23 X
	Book Value Per Share	(13.70) X
	Cash Flow From Operations	(158.42 M)
	Short Ratio	6.08 X
	Earnings Per Share	(5.94) X
	Price To Earnings To Growth	0.81 X
	Target Price	46.14
	Number Of Employees	988
	Beta	0.63
	Market Capitalization	3.48 B
	Total Asset	1.9 B
	Retained Earnings	(3.28 B)
	Working Capital	615.53 M
	Current Asset	355.95 M
	Current Liabilities	45.39 M
	Net Asset	1.9 B

About PTC Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC